NANJING, China, Sept. 12, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamtistomig (LBL-024, PD-L1/4-1BB...
Hence then, the article about indication expansion accelerates first patient dosed in melanoma phase 1b ii trial of opamtistomig was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig )
Also on site :
- ‘The Young and the Restless’ Star Dee Freeman Dead at 66
- “Esto es una recalibración”: el gabinete de Trump teme que nadie esté a salvo tras los despidos de Bondi y Noem
- New Uncharted game teased? Director post hints at franchise return